Febit Acquires License From OGT
News Nov 21, 2005
febit biotech gmbh has announced that it has acquired a license from Oxford Gene Technology (OGT) from Oxford, UK.
The acquired license refers to patents on technologies that were developed in the 80ies by OGT’s founder, Professor Edwin M. Southern.
The "Southern array patents" are the fundamental patents covering the manufacture and use of DNA microarrays in genetic and genomic research.
"We are delighted about the successful conclusion of the agreement with OGT, which further strengthens our IP position to successfully market our GENIOM® technology worldwide," says Cord F. Stahler, President & CEO of febit biotech gmbh.
Dr. Mike Evans, Chief Executive of OGT adds, "We are happy to support febit biotech’s technology by granting this license and thus further the use of microarray technology."
Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain CircumstancesNews
A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.
Genetic Factors Leading to Rare Bone Fusion Disorder IdentifiedNews
Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusionREAD MORE
Hay Fever Risk Genes Overlap with Autoimmune DiseaseNews
In a large international study involving almost 900,000 participants, researchers from the University of Copenhagen and COPSAC have found new risk genes for hay fever. It is the largest genetic study so far on this type of allergy, which affects millions of people around the world.READ MORE